Key result
Essential hypertension linked to ~30% higher risk of incident type 2 diabetes.
Why the study?
Does essential hypertension independently increase the risk and accelerate the onset of incident type 2 diabetes in adults free of baseline diabetes after accounting for metabolic and genetic susceptibility?
Cohort (n=76,439)
Yes
Does essential hypertension independently increase the risk and accelerate the onset of incident type 2 diabetes in adults free of baseline diabetes after accounting for metabolic and genetic susceptibility?
Answers are grounded in this paper and cite their sources.
Hypertension is an independent predictor of earlier and increased type 2 diabetes onset regardless of metabolic profile, antihypertensive drug class, or polygenic predisposition, supporting intensified glycemic surveillance in hypertensive patients.
Hypertension and type 2 diabetes (T2D) frequently coexist, but whether hypertension independently contributes to earlier diabetes onset beyond shared metabolic and genetic susceptibility remains incompletely understood. This study investigates the longitudinal relationship between hypertension and subsequent T2D risk using survival analysis and survival machine learning approaches. A matched cohort analysis was conducted using UK Biobank participants free of diabetes at baseline, and a 6-month lag period was applied to reduce reverse causation. Time-to-event analyses were performed using Cox proportional hazards models. Genetic susceptibility was evaluated using both a genome-wide polygenic risk score (PRS) and a targeted multi-variant score (TMS). Survival machine learning models including XGBoost, Random Survival Forests, and ridge-penalized Cox regression were evalueted under identical train/test splits. Additional robustness analyses incorporated antihypertensive medication classes, genetic principal components, broader hypertension phenotype definitions integrating blood pressure measurements and medication use, stricter baseline diabetes exclusion criteria, extended lag-period analyses, and time-stratified sensitivity analyses. The final multivariable matched analytic cohort included 76,439 participants (37,951 individuals with HTN and 38,488 matched controls). During follow-up, 4,315 incident T2D events occurred, including 3,571 among individuals with HTN and 744 among controls. Hypertension remained independently associated with T2D after adjustment for adiposity, lipid traits, statin use, antihypertensive medication classes, genetic principal components, and genetic susceptibility (HR 1.30, p < 0.001). Individuals with hypertension developed T2D earlier, with reduced diabetes-free survival over follow-up. Both PRS and TMS independently predicted T2D risk and demonstrated significant interactions with hypertension. Survival machine learning analyses showed progressive improvement in discrimination following incorporation of hypertension and genetic susceptibility, with XGBoost demonstrating the highest performance (C-index 0.823, 95% CI 0.812–0.833). Importantly, the observed association remained robust across multiple sensitivity analyses, demonstrating persistence of the association beyond the early post-index period. Hypertension is associated with an increased and earlier T2D risk independent of metabolic risk factors and genetic susceptibility. Polygenic risk further stratifies diabetes risk but does not explain the relationship between hypertension and earlier T2D onset. The consistency of the findings across sensitivity analyses and survival-learning frameworks supports hypertension as an important component of the cardiometabolic trajectory preceding T2D development.
No takes yet. Share an insight, caveat, or question.
Hageh et al. (2026) conducted a cohort in Essential hypertension and risk of type 2 diabetes (n=76,439). Essential hypertension vs. Matched normotensive controls without hypertension before the index date was evaluated on Incident type 2 diabetes (ICD-10 code E11) (HR 1.30, p=<0.001). Essential hypertension independently increased the risk of incident type 2 diabetes (HR 1.30, p<0.001) after adjustment for metabolic risk factors, medications, and genetic susceptibility.
Synapse has enriched 10 related papers. Consider them for comparative context: